Research ArticleBRAIN TUMORS

BCL3 expression promotes resistance to alkylating chemotherapy in gliomas

See allHide authors and affiliations

Science Translational Medicine  04 Jul 2018:
Vol. 10, Issue 448, eaar2238
DOI: 10.1126/scitranslmed.aar2238

BCL3 dampens drug efficacy in gliomas

Chemotherapy with alkylating agents, including temozolomide (TMZ), is the most effective treatment for gliomas, but many patients do not respond to the treatment. Wu et al. now report that high B cell CLL/lymphoma 3 (BCL3) expression promoted resistance to TMZ by activating carbonic anhydrase II. Patients with high BCL3-expressing gliomas showed a poorer response to TMZ and shorter survival than did patients with low BCL3-expressing gliomas. In mice injected with high BCL3-expressing human gliomas, the carbonic anhydrase II inhibitor acetazolamide increased sensitivity to TMZ and survival in the mouse xenograft model. The results suggest that analysis of BCL3 expression might be useful in determining the best therapy for treating gliomas.

View Full Text

Stay Connected to Science Translational Medicine